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MicroRNAs are short regulatory RNAs that are able to
post-transcriptionally modulate gene expression and that
have crucial roles in the control of physiological and
pathological processes including cancer onset, growth,
and progression. miR-214, located inside the sequence of
the long noncoding Dmn3os transcript, contributes to
the regulation of normal and cancer cell biology, even if
it operates in a context-dependent and sometimes
contradictory manner. miR-214 is deregulated in several
human tumors including melanoma, breast, ovarian,
gastric, and hepatocellular carcinomas. miR-214’s pleio-
tropic and tumor-specific contribution to various cancer
formation and progression hallmarks is achieved via its
several target genes. In fact, miR-214 behaves as a key
hub by coordinating fundamental signaling networks
such as PTEN/AKT, b-catenin, and tyrosine kinase recep-
tor pathways. Interestingly, miR-214 also regulates the
levels of crucial gene expression modulators: the epige-
netic repressor Ezh2, ‘‘genome guardian’’ p53, transcrip-
tion factors TFAP2, and another microRNA, miR-148b.
Thus, miR-214 seems to have essential roles in co-
ordinating tumor proliferation, stemness, angiogenesis,
invasiveness, extravasation, metastasis, resistance to che-
motherapy, and microenvironment. The sum of current
literature reports suggests that miR-214 is a molecular
hub involved in the control of cancer networks and,
as such, could be a potential diagnostic/prognostic
biomarker and target for therapeutic intervention.
Journal of Investigative Dermatology (2015) 135, 960–969;
doi:10.1038/jid.2014.479; published online 11 December 2014
INTRODUCTION
MicroRNAs (miRs) are a family of small, 20–25-nucleotide-
long noncoding RNAs with the ability to post-transcriptionally
downregulate the expression of specific target genes. At least a
thousand miRs are predicted to operate in humans, regulating
multiple physiological and pathological cellular processes.
Bioinformatic predictions indicate that miRs are expected to
regulate the expression of around 50% of all protein-coding
genes, thus controlling the activity of a large fraction of the
entire transcriptome (Inui et al., 2010). miR biogenesis and
action mechanisms have been extensively reviewed in the
study by Bartel, (2009). miR-mediated gene expression control
is achieved by specific base pair binding to the 30UTRs of
their target mRNAs, causing either mRNA degradation or
translation inhibition (Filipowicz et al., 2008; Bartel, 2009;
Inui et al., 2010). A single 30UTR can contain numerous
different miR binding sites, and therefore the crucial impact
miRs have on biological processes is mainly because of the
fact that each miR can simultaneously regulate several targets
with disparate functions, making them fundamental regulators
of tumor onset, growth, and progression (Inui et al., 2010).
Cancer cells are characterized by peculiar hallmarks acquired
during the multisteps of tumor progression. These include
sustained proliferation, resistance to cell death, metabolism
reprograming, host microenvironment interactions, angiogen-
esis, invasion, and seeding to distant organs (Hanahan and
Weinberg, 2011). miR deregulation has a crucial role in
cancer as it interferes with these specific hallmarks meaning
miRs can either act as oncogenes or tumor suppressors in the
early disease stages (Croce, 2009) or control the invasive and
metastatic progression of cancer in the latter. Examples of
miRs that control malignancy are miR-10b, miR-373/520c,
miR-9 (pro-metastatic miRs), miR-335, the miR-200 family,
and miR-31 (anti-metastatic miRs; Ma et al., 2007; Huang
et al., 2008; Korpal et al., 2008; Tavazoie et al., 2008;
Valastyan et al., 2009; Ma et al., 2010b). Relevantly, certain
miRs are involved in specific tumor types, for instance the let-
7 family, miR-34 family, miR-137, miR-182, miR-221/222,
and miR-214 control melanoma progression (Mueller and
Bosserhoff, 2009; Penna et al., 2011).
This review focuses on the role of miR-214 in tumor
progression. miR-214 is involved in numerous physiological
and pathological processes including several cancers. The
human miR-214 gene is located in the chromosomal region
1q24.3, in intron 14 of the Dynamin-3 gene (DNM3). As
shown in Figure 1, an almost 8 kb-long noncoding RNA,
named DNM3os, originates from intron 14 of DNM3 in
humans and mice. This transcript contains the sequences for
miR-214 and miR-199a-2, two clustered miRs that are
approximately 6 kb apart. Another small RNA sequence, that
of miR-3120, is also present in this genomic region; however,
it is on the reverse strand (Loebel et al., 2005; Watanabe et al.,
2008; Lee et al., 2009; Yin et al., 2010; Scott et al., 2012).
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Twist-1, ZEB1, Ezh2, NFkB, and SMAD4 have been reported
to control miR-214 and/or DNM3os transcription (Kong et al.,
2008; Juan et al., 2009; Lee et al., 2009; Yin et al., 2010;
Duan et al., 2012; Williams et al., 2012). miR-214 is highly
conserved among species, which indicates that it is involved
in broad physiological functions. In fact, it coordinates the cell
fate, differentiation and morphogenesis of muscles, the
skeleton, nervous system, retina, and pancreas (Flynt et al.,
2007; Joglekar et al., 2007; Decembrini et al., 2009; Chen
et al., 2010a; Shi et al., 2013). High miR-214 expression is
visible early in mouse embryogenesis in the heart, cerebellum,
midbrain, nasal process, and limb buds and reaches a peak at
E12.5. It is downregulated after E15.5 and further decreases in
postnatal tissues, although its expression is detected in
some adult organs, including the lungs, heart, and kidneys
(Watanabe et al., 2008; Aurora et al., 2012). Despite the fact
that miR-214 and miR-199a-2 belong to the same cluster and
are mostly co-expressed during development (Watanabe et al.,
2008), the large distance between them in the locus and their
different seed sequences suggest distinct regulatory mecha-
nisms and biological functions. Disruption of the entire mouse
DNM3os locus leads to skeletal abnormalities and death
within 1 month after birth (Watanabe et al., 2008). However,
ubiquitous miR-214-specific knockout mice are viable and
fertile, while displaying heart defects and cardiac contractility
loss following ischemia-reperfusion injury (Aurora et al.,
2012), whereas bone-specific miR-214-overexpressing mice
show defective osteogenic differentiation and bone formation
(Wang et al., 2013c). A specific miR-199a knockout mouse
model is, however, necessary to clarify the contributions of
miR-214 and miR-199a and to determine whether the
differences between DNM3os and miR-214-null mice are
due to the combination of these two miRs or due to the
specific functions of the long noncoding RNA.
If we consider the fact that embryonic stemness and
differentiation programs are often reactivated during tumor
progression, the hypothesis that miR-214 has a role in
tumorigenesis is well-grounded.
MIR-214 DOUBLE-FACED DEREGULATION IN CANCER
miR-214 is deregulated in several human cancers and displays
contrasting behavior, thus suggesting that cell context is
crucial for miR-214 function (Table 1).
Cutaneous cancers
There are three main types of skin cancers; basal cell
carcinoma, Squamous Cell Carcinoma (SCC), and malignant
melanoma. miR-214 is often altered in these, but particularly
in melanoma, which is the least common but often most fatal
of dermatologic tumors.
Although normal melanocytes display low miR-214 levels,
the expression of this small RNA is high in nevi, which
present abnormal, although benign, melanocyte proliferation
and frequently contain genetic mutations (Grichnik, 2008;
Glud et al., 2009; Philippidou et al., 2010; Chen et al., 2010b;
Penna et al., 2011). Importantly, miR-214 is highly expressed
in primary malignant cutaneous melanomas (Molnar et al.,
2008; Segura et al., 2010; Penna et al., 2011, 2013), although
showing low expression levels in in situ noninvasive
melanomas (Penna et al., 2011). Moreover, miR-214
correlates significantly more with acral than with non-acral
melanoma subtypes (Chan et al., 2011) and is heavily
expressed and associated with poor prognosis and elevated
metastatic risk in ocular melanomas (Worley et al., 2008).
However, miR-214 levels may be slightly lower in metastases
than in primary tumors, thus suggesting that this miR-214
increase has an important role at the time of radial to vertical/
invasive melanoma growth (Penna et al., 2011). Nevertheless,
miR-214 upregulation in melanoma metastases is also asso-
ciated with longer post-recurrence survival (Segura et al.,
2010). It is also important to note that miR-214 resides in a
genomic region that is frequently amplified in melanoma, as
demonstrated by Comparative Genomic Hybridization (CGH)
in the study by Zhang et al., (2006), whereas no reports
indicate any correlation between miR-214 expression and
typical melanoma genetic lesions, such as BRAF or KRAS
mutations, to our knowledge. miR-199a-2, located in the same
cluster as miR-214, is also amplified (Zhang et al., 2006) and
deregulated (Pencheva et al., 2012) in melanoma. Patients
with high miR-199a-3p and miR-199a-5p levels in primary
melanomas show shorter metastasis-free survival compared
with patients expressing low levels of these miRs (Pencheva
et al., 2012). Accordingly, high miR-199a levels in ocular
melanomas correlate with metastatic risk (Worley et al.,
2008). As described in the following sections, miR-214 and
miR-199a’s involvement in driving melanoma metastasis has
been clearly demonstrated (Penna et al., 2011; Pencheva
et al., 2012; Penna et al., 2013).
Although miR-214 is well expressed in epidermal keratino-
cytes and hair follicles and is relevant in skin morphogenesis
(Ahmed et al., 2012), contrasting observations have been
reported regarding SCC and basal cell carcinoma. In fact, miR-
214 is upregulated in oral and tongue SCC (Scapoli et al.,
2010; Yu et al., 2010), whereas it was found to be significantly
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Figure 1. Genomic location of human miR-214. miR-214 and miR-199a-2 are 6 kb apart, located inside the 7.9 kb-long noncoding RNA precursor, DNM3os, in
intron 14 of the Dynamin-3 (DNM3) gene (1q24.3). miR-3120 overlaps the miR-214 locus but in its complementary strand.
E Penna et al.
miR-214 Coordinates Cancer Networks
www.jidonline.org 961
downregulated in esophageal and cutaneous SCC, leading to
abnormal keratinocyte proliferation (Huang et al., 2012;
Yamane et al., 2013). miR-214 expression seems not to be
involved in basal cell carcinoma, however (Sand et al., 2012).
Various non-cutaneous tumors
miR-214 is upregulated in pancreatic (Volinia et al., 2006;
Zhang et al., 2010), prostate (Volinia et al., 2006), stomach
(Volinia et al., 2006; Ueda et al., 2010; Li et al., 2011; Yang
et al., 2013; Wang et al., 2014a), nasopharyngeal (Deng et al.,
2013; Zhang et al., 2014), and lung (Yanaihara et al., 2006)
tumors, as well as in osteosarcomas (Xu and Wang, 2014;
Wang et al., 2014c) and in a leukemic variant of cutaneous
T-cell lymphomas, the Sezary syndrome (Narducci et al.,
2011), as compared with healthy tissues. High miR-214
expression has been associated with unfavorable prognosis
in overall survival and clinical staging, invasiveness,
metastasis, and poor response to therapy (Ueda et al., 2010;
Narducci et al., 2011; Yang et al., 2013; Wang et al., 2014c).
Conversely, noteworthy miR-214 downregulation occurs in
hepatocellular (Duan et al., 2012; Shih et al., 2012; Wang
et al., 2012a, 2013b), uterus cervix (Yang et al., 2009),
adrenocortical (Tombol et al., 2009), bladder (Ratert et al.,
2013), colorectal (Chen et al., 2014), and cholangio (Li et al.,
Table 1. MicroRNA-214 alterations in cancer
Tumor
miR-214 expression in
tumor vs. normal tissue
miR-214 correlation with
metastasis or poor prognosis Validated miR-214 targets References
Melanoma Up
Down
Yes
Yes
TFAP2, ITGA3 Penna et al., 2011
Worley et al., 2008
Segura et al., 2010
Pancreas Up — ING4 Zhang et al., 2010
Volinia et al., 2006
Stomach Up Yes PTEN Volinia et al., 2006
Ueda et al., 2010
Yang et al., 2013
Prostate Up — — Volinia et al., 2006
Nasopharygeal Up — LTF, BIM Deng et al., 2013
Zhang et al., 2014
Oral/tongue squamous Up — — Yu et al., 2010
Scapoli et al., 2010
Osteosarcoma Up Yes LZTS1 Wang et al., 2014c
Xu and Wang, 2014
T-cell lymphoma Up Yes — Narducci et al., 2011
Lung Up — — Yanaihara et al., 2006
Hepatocellular Down Yes HDGF, XBP1, EZH2,
FGFR1, b-catenin
Shih et al., 2012
Xia et al., 2012
Wang et al., 2013b
Uterus cervix Down Yes PLXNB1, GALNT7, MEK3, JNK1 Yang et al., 2009
Qiang et al., 2011
Adrenocortical Down — — Tombol et al., 2009
Esophageal Down — — Huang et al., 2012
Cutaneous squamous Down — ERK1 Yamane et al., 2013
Myeloma Down — ASF1B, GANKYRIN Gutierrez et al., 2010
Bladder Down Yes — Ratert et al., 2013
Glioma Down Yes UBC9 Wang et al., 2014b
Colorectal Down Yes FGFR1 Chen et al., 2014
Rhabdomyosarcoma Down — NRAS Huang et al., 2014
Ovary Up
Down
Yes
Yes
PTEN, p53 Yang et al., 2008
Marchini et al., 2011
Iorio et al., 2007
Breast Up
Down
Yes
Yes
EZH2 Derfoul et al., 2011
Schwarzenbach et al., 2012
Blenkiron et al., 2007
MicroRNA-214 (miR-214) altered expression (up- or downregulation) in different types of human cancers. Where possible, the correlation with metastasis/poor
prognosis and malignancy-involved validated targets is indicated.
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2012) carcinomas, as compared with healthy tissues, as well
as in multiple myelomas (Gutierrez et al., 2010), gliomas
(Wang et al., 2014b), and in lung adenocarcinoma-derived
brain metastases (Zhao et al., 2013). In these neoplasias, miR-
214 reduction is often associated with malignancy, metastasis,
or poor survival/recurrence (Qiang et al., 2011; Li et al., 2012;
Xia et al., 2012; Ratert et al., 2013; Wang et al., 2013b; Chen
et al., 2014).
miR-214 displays more complex behavior in breast and
ovary cancers, possibly due to high tumor heterogeneity and
hormone responsiveness. The miR-214 locus is frequently
amplified in these tumors, as shown by CGH (Zhang et al.,
2006); however, it has been found to have been deleted in
24% of a small group of breast cancer cases (Derfoul et al.,
2011). miR-214 is less expressed in large cohorts (Dvinge
et al., 2013) of breast tumor samples than in normal tissues,
whereas its upregulation has been found in Luminal A,
Normal-like and ER-,PR-,HER2þ / breast cancer subtypes
(Blenkiron et al., 2007; Sempere et al., 2007). Similarly, miR-
214 is overexpressed in ovary cancers and significantly
associated with high grade and late/metastatic tumor stages,
as well as with overall and progression-free survival and post-
surgical/chemotherapy recurrence (Yang et al., 2008;
Marchini et al., 2011). However, miR-214 downregulation
has also been described in neoplastic, as compared with
normal, ovaries, as well as in ovary cancer–derived effusions
as compared with primary tumors (Iorio et al., 2007; Vaksman
et al., 2011).
These data, taken as a whole, suggest that miR-214
deregulation could have a relevant impact on malignancy,
even if it can operate in opposite manners in different tumors.
Therefore, it should be evaluated for diagnostic/therapeutic
purposes.
CIRCULATING MIR-214 AS A DIAGNOSTIC MARKER
Interestingly, miR-214 has been observed to be a circulating
miR, and its serum levels have shown diagnostic potential. In
fact, analyses of miR-214 levels in the serum of over 100
breast cancer patients were able to discriminate between
malignant and benign tumors, as well as healthy controls,
whereas levels were significantly decreased in post-operative
sera but increased in association with metastatic spread
to regional lymph nodes (Schwarzenbach et al., 2012).
miR-214 blood serum expression was also able to identify
patients carrying malignant peripheral nerve sheath
tumors (Weng et al., 2013). Similarly, the analysis of
circulating exosomes isolated from ovarian carcinoma
patients revealed the presence of miR-214 (overexpressed
in the primary tumor mass), together with 7 other miRs,
which strongly supports the case for miR-214’s diagnostic
power (Taylor and Gercel-Taylor, 2008). The same situation
was observed when exosomes from lung cancer patients
were analyzed (Rabinowits et al., 2009). Furthermore,
urinary miR-214 has been proven to be a diagnostic
biomarker for bladder and prostate cancers (Kim et al.,
2013; Srivastava et al., 2013). These observations reinforce
the potential of extracellular miR-214 use as a diagnostic or
prognostic biomarker.
MIR-214 FUNCTIONS AND TARGETS IN TUMOR
PROGRESSION
Altered miR-214 expression in cancer has led numerous
researchers to investigate its tumor-specific functions and to
identify its targets in the various tumor formation and pro-
gression steps. miR-214’s pleiotropic roles and direct targets
are summarized in Figure 2 and discussed below.
Proliferation, cell cycle, and survival
Altered levels of miR-214 in tumors seem to hint at a possible
influence on proliferation and cell cycle control; however,
existing data are controversial. No positive miR-214 cell
viability or growth regulation was observed in melanomas
(Penna et al., 2011), lung (Fei et al., 2008), or pancreatic
(Zhang et al., 2010) carcinomas. By contrast, miR-214 was
found to promote AKT signaling, proliferation, and survival in
gastric tumors via PTEN and in nasopharyngeal carcinomas
via lactoferrin and Bim targeting (Deng et al., 2013; Yang
et al., 2013; Zhang et al., 2014), and to favor osteosarcoma
growth via LZTS1 repression (Xu and Wang, 2014). On the
other hand, miR-214 inhibits proliferation in breast or hepatic
carcinomas via Ezh2, b-catenin, and XBP1 (an ER-stress-
induced pro-survival factor) targeting; miR-214 expression
also reduces hepatoma xenograft growth (Derfoul et al.,
2011; Duan et al., 2012; Shih et al., 2012; Xia et al., 2012;
Wang et al., 2012a). Furthermore, proliferation is decreased
by miR-214 in rhabdomyosarcomas via N-Ras oncogene
suppression (Huang et al., 2014), in cervical cancers via
MEK3 and JNK1, GALNT7 and Plexin-B1 downregulation
(Cheng et al., 2005; Yang et al., 2009; Qiang et al., 2011;
Peng et al., 2012), and in squamous cell carcinoma cells via
ERK1 inhibition (Yamane et al., 2013). In myelomas, miR-214
targets ASF1B and gankirin, thus inducing p53, p21, and Bax
upregulation and resulting in the inhibition of DNA replication
and apoptosis (Misiewicz-Krzeminska et al., 2013). A link
between miR-214 and Receptor Tyrosine Kinases (RTKs) was
also observed. In fact, miR-214 targets FGFR1 in hepato-
cellular and colorectal carcinomas, thus influencing cell
growth (Wang et al., 2013b; Chen et al., 2014), and the
ErbB3 cis-interactor Necl-2, leading to enhanced ErbB2/3
signaling in colon carcinomas (Momose et al., 2013).
Angiogenesis
Tumor vascularisation has a central role to play in cancer
progression. Indeed, neo-angiogenesis within the tumor mass
provides cancer cells with the blood vessels necessary for
growth and, in the meanwhile, facilitates the intravasation and
dissemination of metastatic cells. On the other hand, hypoxic
conditions, caused by insufficient or aberrant vascularization,
often contribute to the selection of more malignant tumor cell
subpopulations (Carmeliet and Jain, 2011). Interestingly, miR-
214 has a key role in angiogenesis. It is expressed in
endothelial cells (Wurdinger et al., 2008; Rippe et al., 2012)
and inhibits HUVEC angiogenesis and vascular network
formation by targeting Quaking and, consequently, reduces
the secretion of pro-angiogenic growth factors and cytokines,
including VEGF, CCL5, and CXCL5 (van Mil et al., 2012). In
addition, miR-214 downregulates the eNOS (nitric oxide
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synthase) enzyme, which is essential for endothelial cell
migration (Chan et al., 2009). By contrast, adult endothelial
cells (HMEC-1) secrete miR-214-containing exosomes which,
in turn, stimulate a pro-angiogenic program in neighboring
cells via ATM downregulation (van Balkom et al., 2013).
Considering the cross talk between tumor and endothelial
cells within a tumor mass, the existence of a pivotal role for
miR-214 can be envisaged in tumor vascularization. Indeed,
miR-214 downregulation in hepatocellular carcinoma contri-
butes to tumor angiogenesis, whereas its ectopic overexpres-
sion reduces tumor growth and vascularity. This occurs via its
direct target, hepatoma-derived growth factor (HDGF; Shih
et al., 2012), thus demonstrating that miR-214 has an anti-
angiogenic role in hepatocarcinomas, in which miR-214
downregulation is associated with worse clinical outcome.
Migration, invasion, extravasation, and metastasis
miR-214 upregulation in melanoma cell lines significantly
promotes tumor cell migration, invasion, adhesion to extra-
cellular matrices, transendothelial migration, and survival to
anoikis in vitro, as well as extravasation from blood vessels
and metastasis formation in mice. This occurs without affect-
ing cell proliferation and tumor growth via the simultaneous
coordination of a network including over 70 genes (Penna
et al., 2011). In particular, miR-214 acts by directly targeting
transcription factors TFAP2, well-established melanoma tumor
suppressors, and upregulating ALCAM, an adhesion receptor
known as a melanoma progression marker. ALCAM upregu-
lation occurs via TFAP2 and miR-148b, a small RNA that is
downregulated by miR-214. Rescuing experiments have
demonstrated that TFAP2 or miR-148b downmodulation and
ALCAM upregulation control miR-214-dependent melanoma
metastatic traits and metastasis formation (Penna et al., 2011,
2013), thus highlighting the importance of a critical pathway
that involves these players. Importantly, several miR-148b
target genes, including ALCAM, ROCK1, PIK3CA, and
ITGA5, are upregulated by miR-214, because of miR-148b
downmodulation, which could account for additional miR-
214 pro-malignant functions (Penna et al., 2013; Orso et al.,
unpublished data). Moreover, the miR-214-dependent
modulation of other genes in this network may influence
melanoma progression, as well. These include genes that
regulate adhesion, movement, invasion, and matrix degra-
dation (integrins, cadherins, MCAM, NCAM, BCAM, PAK2,
MMP2, ADAMs, TIMPs and the MET oncogene), others that
are implicated in interactions with endothelial cells and
extravasation (E-Selectin, CD9, IL-8, SEMA3A, VEGFR2, VEGFA
and ALCAM itself), and still others that are members of the
TGFb, Wnt, and Notch pathways and that are potentially
involved in the epithelial-to-mesenchymal transition. These
findings appear to indicate a clear pro-invasive and pro-
metastatic role played by miR-214 in melanoma. Nevertheless,
other authors have observed, in a similar context, the exi-
stence of a significant role for the small RNA that is clustered
miR-214
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Figure 2. miR-214 controls cancer networks. miR-214 direct target genes and indirect downstream players are shown, together with their multiple functions in
tumor cells (different colors).
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with miR-214, miR-199a-2. Indeed, both miR-199a-5p and
miR-199a-3p have been demonstrated to strongly drive mela-
noma invasion and metastatic colonization and to enhance
angiogenesis by synergistically targeting ApoE and DNAJA4
and thus controlling the LPR1 and LPR8 pathways (Pencheva
et al., 2012). It is possible that miR-214 and miR-199a operate
in an alternative or synergistic manner in melanoma pro-
gression, and detailed experiments need to be performed to
unravel the precise functions of these two clustered miRs.
miR-214 significantly encourages migration and invasion in
gastric cancer by targeting PTEN (Yang et al., 2013), whereas
it favors osteosarcoma invasion by silencing LZTS1 (Xu and
Wang, 2014), and, furthermore, nasopharyngeal carcinoma
metastasis formation has been found to be promoted via
lactoferrin repression in a mouse xenograft model (Deng
et al., 2013). miR-214 has been shown to display pro-
invasive or pro-metastatic properties in mammary tumor
cells (Penna et al., 2011), although a deeper analysis of
miR-214 functions in breast cancer is still pending. Indeed,
Derfoul and colleagues have reported opposite data:
decreased miR-214 levels in mammary carcinoma cells
correlate with increased cell invasion via the accumulation
of miR-214 target, Ezh2, a known marker of malignancy that
coincides with the histone H3K27 trimethylation catalytic
subunit of the Polycomb repressive complex 2, which epi-
genetically regulates chromatin and thereby influences gene
expression (Derfoul et al., 2011; Crea et al., 2012). Similarly,
miR-214 suppresses cell invasion by downregulating Ezh2,
b-catenin, and FGFR1 in hepatocellular carcinoma cells; the
high expression of these genes correlates with low miR-214
levels and increased malignancy (Xia et al., 2012; Wang et al.,
2013b). Importantly, sustained b-catenin and/or Ezh2 expres-
sion in breast or hepatic tumors leads to malignancy as the
levels of their downstream genes, such as c-Myc, cyclin D1,
TCF-1, LEF-1, E-cadherin, SFRP3, IGFBP2, and even b-catenin
itself, are affected (Derfoul et al., 2011; Xia et al., 2012; Wang
et al., 2012a). Interestingly, Ezh2 repression by miR-214 in
esophageal squamous carcinoma cells also results in migra-
tion and invasion inhibition (Huang et al., 2012). Furthermore,
miR-214 has been shown to inhibit invasion via Plexin-B1 and
GALNT7 targeting in cervical cancers (Qiang et al., 2011;
Peng et al., 2012), via FGFR1 repression in colorectal tumors
(Chen et al., 2014) and via Twist-1 (a master regulator of
metastasis) downregulation in intrahepatic cholangiocarci-
nomas (Li et al., 2012).
Chemoresistance
Despite the controversial findings concerning the role of
miR-214 in proliferation, one of the first miR-214 functions
described was its ability to reduce apoptotic cell death,
contributing to decreased chemotherapy sensitivity, the main
cause of treatment failure and disease progression. In parti-
cular, miR-214 has been shown to inhibit cisplatin-induced
apoptosis in human ovarian cancers primarily by targeting
PTEN and enhancing the AKT pathway and survival (Yang
et al., 2008). Moreover, miR-214 has been proven to
contribute to cisplatin chemoresistance in tongue squamous
cell carcinomas (Yu et al., 2010). Accordingly, miR-214 is
significantly upregulated in gefitinib-resistant EGFR-mutant
non-small cell-lung cancer cells. PTEN targeting also has a
major role in this case. In fact, miR-214 knockdown is suffi-
cient to normalize AKT pathway activation and to resensitize
cells to the therapy (Wang et al., 2012b). Furthermore, miR-
214 overexpression in pancreatic cancer cells decreases sensi-
tivity to gemcitabine, the first line treatment for advanced
pancreatic cancers, probably via its direct target ING4, a gene
involved in cell cycle arrest, DNA repair, and apoptosis
(Zhang et al., 2010). Moreover, high miR-214 levels have
been associated with poor chemotherapy response in pediatric
osteosarcomas (Wang et al., 2014c) and with increased T-cell
lymphoma cell survival and apoptotic resistance (Narducci
et al., 2011). Finally, miR-214 has been predicted to control
paclitaxel sensitivity in laryngeal cancer cells (Xu et al., 2013).
The only study that has published contrary results was
performed in cervical cancer cells where miR-214 enhances
cisplatin-induced cytotoxicity, via the downregulation of
Bcl2l2 (Wang et al., 2013a). In melanomas, miR-214
reduces apoptosis and facilitates survival in adhesion-lacking
(anoikis) conditions (Penna et al., 2011), which would seem to
suggest a potential role in chemoresistance; however, the
details of its actual involvement are still to be explored.
Cancer stemness
miR-214 has a key role in normal cell differentiation by
targeting Ezh2 (see above), which leads to the consequent
derepression of the master developmental regulators Gata-4,
Pax7, and Sox17 (Juan et al., 2009). As developmental
pathways are often reactivated during tumorigenesis and
stemness markers are observed in tumor stem cells (Nguyen
et al., 2012), the involvement of miR-214 in cancer stem cells
has been investigated and confirmed. In fact, miR-214 has
been shown to regulate ovarian cancer stem cell properties by
directly repressing p53 and indirectly upregulating Nanog,
leading to increased stem cell population and self-renewal (Xu
et al., 2012). However, lower miR-214 expression has been
reported in ovarian cancer stem cells than in mature cells, and
here the miR-214-controlled PTEN-AKT pathway is seen to be
a major regulator of stemness (Yin et al., 2010). Interestingly,
miR-214 was found to be the most highly expressed of a list
of 37 differentially expressed small noncoding RNAs in an
analysis of miR expression in purified CD44þCD24-lin- breast
cancer stem cells (Shimono et al., 2009). miR-214 expression
has also been found to be significantly increased in pancreatic
cancer cell–derived holoclones, which are capable of long-
term survival, tumor initiation, and chemoresistance (Tan
et al., 2011). In contrast, miR-214 has been demonstrated to
suppress stem-like traits in human hepatocellular carcinoma
cells by directly targeting Ezh2 and b-catenin signaling
pathways (Xia et al., 2012). These findings indicate that
miR-214 has contrasting functions in controlling cancer
stemness, depending on its role in specific malignancies.
Tumor-associated stroma
Cancer-associated fibroblasts (CAFs) have a major role in the
tumor microenvironment; however, the conversion of quies-
cent fibroblasts into CAFs is still quite a mystery. miR-214 is
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relevant in this process as ovarian cancer cells, in fact, induce
miR-214 downregulation in normal tumor-adjacent fibro-
blasts, thus reprograming them into CAFs with increased
chemokine secretion. A particular example is CCL5, which
is a direct miR-214 target (Mitra et al., 2012). On the other
hand, miR-214 is upregulated in gastric cancer–derived
mesenchymal stem cells, which are involved in invasion
(Wang et al., 2014a).
CONCLUDING REMARKS
In conclusion, miR-214 appears to be a pleiotropic hub that
participates in the control of cancer cell signaling networks. In
fact, it contributes to the coordination of essential signaling
pathways, such as the PTEN/AKT, b-catenin, or receptor
tyrosine kinase pathways, as well as crucial gene expression
modulators, including Ezh2, p53, TFAP2, and miR-148b. The
fact that miR-214 displays specific and even contrasting
functions in different tumor types is most likely due to
differential mRNA targeting and/or target gene expression in
different cancer cell contexts. In particular, as miR-214 broadly
controls gene expression by regulating transcription factors and
other miRs, disparities in the expression of subsets of these
downstream players in different tumors, or tumor cell popula-
tions, may account for the versatility of miR-214 actions. Thus,
miR-214 may have contrasting roles according to co-expression
with its own direct or indirect target genes or with other miRs
(for instance miR-148b or the clustered miR-199a-2) and their
targets. This may also explain the switch between proliferation/
survival phenotypes in certain cancers to movement/invasion
traits in others. Importantly, some known miR-214-regulated
genes (e.g., TFAP2 and ALCAM) display contrasting behavior in
different tumor types in which miR-214 also has contrasting
functions. For instance, although TFAP2 factors are well-defined
tumor suppressors in melanoma and are often lost during
disease progression (Bar-Eli, 2001), their role in breast tumors
is more complex. In fact, TFAP2A is frequently upregulated in
ErbB2/HER2-positive breast carcinomas and induces ErbB2/
HER2 transcription (Bosher et al., 1996; Turner et al., 1998;
Shiu et al., 2014). However, other studies have observed
reduced TFAP2 levels in high grade and metastatic breast
cancers (Pellikainen et al., 2002; Sotiriou et al., 2006).
Moreover TFAP2C overexpression in a MMTV/Neu transgenic
mouse model resulted in reduced tumorigenesis (Jager et al.,
2005). Similarly, high ALCAM positivity is a clinical marker for
melanoma thickness and invasiveness (van Kempen et al.,
2000). ALCAM upregulation, as opposed to normal mammary
tissue, has furthermore been observed in intraductal/invasive
breast carcinomas (Burkhardt et al., 2006) and correlates with
metastasis, as well (Piao et al., 2012). However, low ALCAM
levels have also been associated with mammary nodal
infiltration, metastatic dissemination, and worse clinical
outcome (King et al., 2004; Jezierska et al., 2006).
Tumor mouse models are essential to an improved defini-
tion of miR-214 involvement in cancer, and as such other
tissue-specific miR-214-deleted or miR-214-overexpressing
mice need to be established and analyzed for this purpose,
in addition to existing animal models (Aurora et al., 2012;
Wang et al., 2013c). Additional investigations must carefully
evaluate miR-214 genomic locus and transcriptional/post-
transcriptional events if we want to understand how miR-
214 deregulation occurs in cancer. Furthermore, circulating
miR-214 has been proven to be a potential biomarker
(Schwarzenbach et al., 2012), and therefore its diagnostic/
prognostic value should be explored in depth and in various
tumors. Finally and more importantly, as miR-based in vivo
therapy attempts have already been successful (Care et al.,
2007; Elyakim et al., 2010; Wiggins et al., 2010; Ma et al.,
2010a), the potential use of miR-214 as a therapy target merits
careful investigation.
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